An interventional study of "Exp-ED" Digital Exposure-Therapy Chatbot app in Eating Disorders, Anorexia Nervosa and Bulimia Nervosa, sponsored by Milton S. Hershey Medical Center. Recruiting at 1 site in United States. Open to participants aged 12 Years to 26 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 259 studies in Feeding and Eating Disorders with a site in United States — 35 open to participants now, 49 under way, none of them phase 3. Feeding and Eating Disorders · United States.
Among the 259 studies in Feeding and Eating Disorders with a site in United States, this one is the 172nd largest by planned enrollment of the 215 interventional ones that give a count, is one of 14 that started in 2026, is one of 169 with no phase, reaches primary completion later than 25 of the 48 other live ones, and was the 243rd registered.
645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.
Browse Feeding and Eating Disorders studies →35 of the 259 studies in Feeding and Eating Disorders with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages up to 6 mo
Duke University · Sites in United States
Ages 15–25
Duke University · Sites in United States
Ages 18–25
Washington University School of Medicine · Sites in United States
Ages 18+
Trustees of Dartmouth College · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.
This study: 12 Years to 26 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
259 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 19 · Phase 3 7 · Phase 4 6
First in 1995; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 71 across 452 interventional studies indexed under Feeding and Eating Disorders.
Median enrollment 66 across the 215 interventional studies, 90 across the 43 observational. Of the 201 that completed or were terminated, 49 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 259 have an industry lead sponsor. The 10 most frequent:
Milton S. Hershey Medical Center is the lead sponsor of 493 studies on the registry; 60 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.
Milton S. Hershey Medical Center has 5 studies filed under Feeding and Eating Disorders — fewer than ten, so there is no comparison to draw.
28 of the studies in Feeding and Eating Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858774Icahn School of Medicine at Mount SinaiUse of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder | 2026-11 |
| NCT06532734Denver Health and Hospital AuthorityBarrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype | 2026-11 |
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT05509257Children's Mercy Hospital Kansas CityNaltrexone Neuroimaging in Teens With Eating Disorders | 2026-12 |
| NCT07589621Florida State UniversitySafety Behavior Fading Versus Progressive Muscle Relaxation for Appearance Concerns | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 259 studies in Feeding and Eating Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to develop and refine an artificial intelligence (AI)-powered Exposure Therapy for Eating Disorders chatbot web-app that effectively engages adolescents and young adults and decreases anxiety about weight gain. Participants will use the web-app as a supplemental therapeutic tool during their first six weeks of treatment in a Partial Hospitalization Program. Participants will complete assessments every two weeks, including: (1) semi-structured interviews about their experience with the chatbot web-app; (2) implementation outcome measures (e.g., feasibility, usability, acceptability); and (3) anxiety about weight gain.
The overarching goal of this study is to develop and refine an AI-powered Exposure Therapy for Eating Disorders (Exp-ED) chatbot app that effectively engages adolescents and young adults (AYAs) with eating disorders (EDs) and decreases anxiety about weight gain. The investigators will enroll 20 AYAs (ages 12-26 years) entering the Partial Hospitalization Program (PHP) for EDs at the Penn State Milton S. Hershey Medical Center. The initial version of the Exp-ED chatbot app will be developed by an interdisciplinary team with expertise in exposure therapy for EDs (Dr. Essayli), AI (Dr. Nawab), and implementation science (Dr. Lenker). Participants will use the Exp-ED chatbot app as a supplemental therapeutic tool during their first six weeks of PHP treatment. Participants will complete assessments every two weeks, including: (1) semi-structured interviews about their experience with the Exp-ED chatbot app, including design issues and engagement barriers; (2) implementation outcome measures (e.g., feasibility, usability, acceptability); and (3) anxiety about weight gain. Success will be evaluated using pre-determined benchmarks derived from previous mental health chatbot research. This project has two aims:
Aim 1: Iteratively adapt an exposure therapy chatbot app for AYAs with EDs. The investigators will conduct monthly reviews of mixed-methods data and use the Framework for Reporting Adaptations and Modifications-Enhanced (FRAME) to systematically document and evaluate modifications to the chatbot app. Each revised version will be tested with new participants, creating an iterative development process that continues throughout the project period. All adaptation decisions and their empirical foundations will be documented to create a comprehensive record of the app's development via implementation science frameworks.
Aim 2. Evaluate the feasibility, usability, acceptability, and preliminary efficacy of the Exp-ED chatbot app. H2.1: The investigators will recruit ≥50% of eligible AYAs with EDs. H2.2: Over the six-week project period, participants will use the app ≥18 times. H2.3: Participants will engage with the chatbot for ≥100 minutes total. H2.4: Participants will rate the Exp-ED chatbot app as acceptable (score ≥68 on the System Usability Scale). H2.5: Participants will report a ≥50% reduction in anxiety about weight gain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exp-ED will target anxiety about weight gain through an exposure based treatment.
Behavioral: "Exp-ED" Digital Exposure-Therapy Chatbot app
Exp-ED is a text-based digital health application designed for smartphones and personal computers. It provides exposure-based content to adolescents and young adults with eating disorders. The chatbot guides users through exposure exercises (structured steps to reduce anxiety over time), records subjective distress ratings (self-reported anxiety scores), and offers evidence-based coping prompts. These sessions are intended to supplement clinical care during a six-week partial hospitalization program.
Number of times participants use web-app.
The investigators will measure the number of times participants use the web-app
Time frame: End of Week 2, End of Week 4, End-of-Treatment (Week 6)
Number of minutes participants engage with the web-app.
The investigators will measure the number of minutes participants engage with the web-app
Time frame: End of Week 2, End of Week 4, End-of-Treatment (Week 6)
Percent of eligible Adolescents and Young Adults Consented
The investigators will measure the percent of eligible adolescents and young adults who consent to the study.
Time frame: Through study completion, an average of 1 year
System Usability Scale Survey (SUS)
The System Usability Scale Survey (SUS) is a 10-item self-report questionnaire that examines the participant's attitude towards the web-app. Scores range from 10-50, with higher scores indicating a better overall experience with the app.
Time frame: End of Week 2, End of Week 4, End-of-Treatment (Week 6)
Weight Gain Anxiety Questionnaire
The Weight Gain Anxiety Questionnaire is a 12-item self-report questionnaire that targets anxiety about weight gain. The scores are measured on a 0-100 scale, with the higher the score indicating more distress about weight gain, with the exception for question 12 which is reverse scored.
Time frame: Baseline, End of Week 2, End of Week 4, End-of-Treatment (Week 6)
Clinical Impairment Assessment (CIA)
The Clinical Impairment Assessment Questionnaire (CIA) is a 16-item self-report measure of the severity of psychosocial impairment due to eating disorder features and focuses on the past 28 days. The 16 items cover impairment in domains of life that are typically affected by eating disorder psychopathology: mood and self-perception, cognitive functioning, interpersonal functioning, and work performance. The responses are scored 0,1,2 and 3, with a higher rating indicating a higher level of impairment. The total range is between 0 and 48.
Time frame: Baseline, End-of-Treatment (Week 6)
Eating Disorder Examination - Self-Report Questionnaire (EDE-Q)
The Eating Disorder Examination Questionnaire (EDE-Q) is a 28-item self-report questionnaire. It was designed to assess the range, frequency, and severity of behaviors associated with a diagnosis of an eating disorder. A global score is obtained by summing the four subscales scores (ranging from 0-6) and dividing the total by the number of subscales (4). The score of items are calculated and range from 0 to 6. The higher score indicate greater ED symptoms.
Time frame: Baseline, End-of-Treatment (Week 6)
Eating Disorder Fear Questionnaire (EDFQ)
The Eating Disorder Fear Questionnaire (EDFQ) is a 20-item self-report questionnaire. It examines the participant's severity of behaviors associated with a diagnosis of an eating disorder. The response range between 1 to 7 with a total range of 20 to 140. The higher rating indicates a higher severe impairment.
Time frame: Baseline, End-of-Treatment (Week 6)
Fear of Food Measure (FOFM)
The Fear of Food Measure (FORM) is a 23-item self-report questionnaire. It examines the participant's severity of behaviors associated with a diagnosis of an eating disorder. Each item is scored on a 1-7 scale. The questionnaire range from 23 to 161 meaning 23: no fear of food and 161 meaning severe fear of food.
Time frame: Baseline, End-of-Treatment (Week 6)
Generalized Anxiety Disorder-7 (GAD-7)
The Generalized Anxiety Disorder-7 is a 7-item self-report questionnaire that targets anxiety symptoms. The scores range from 0 to 21, with higher scores indicating higher levels of anxiety.
Time frame: Baseline, End-of-Treatment (Week 6)
Patient Health Questionnaire-9 (PHQ-9)
The Patient Health Questionnaire-9 is a 9-item self-report questionnaire that targets depressive symptoms. The scores range from 0-27, with higher scores indicating a higher level of depression.
Time frame: Baseline, End-of-Treatment (Week 6)
Eating Anxiety Questionnaire
The Eating Gain Anxiety Questionnaire is a 14-item self-report questionnaire that targets anxiety about eating fear foods. The scores are measured on a 0-100 scale, with the higher the score indicating more distress about eating fear foods, with the exception for question 12 which is reverse scored.
Time frame: Baseline, End of Week 2, End of Week 4, End-of-Treatment (Week 6)
Columbia Suicide Severity Rating Scale (CSSRS)
Evidence-based metric evaluating for presence of suicidal ideation and severity. Scores range from 1 (low risk) to 3 (high risk).
Time frame: Baseline
Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.
Of 267 non-industry interventional studies with no phase under Feeding and Eating Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 15 months is below that.
Counting every sponsor, half of 272 studies reached it within 28 months; a quarter within 14 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Feeding and Eating Disorders →
Milton S. Hershey Medical Center →